Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ultra-concentrated rapid acting insulin aspart - Arecor

Next Previous
Drug Profile

Ultra-concentrated rapid acting insulin aspart - Arecor

Alternative Names: AT-278; Ultra-concentrated rapid acting insulin - Arecor

Latest Information Update: 27 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arecor
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diabetes mellitus
  • Phase I Type 2 diabetes mellitus
  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 27 Jun 2025 Phase-II clinical trials in Diabetes mellitus (SC), prior to June 2025 (Arecor pipeline, June 2025)
  • 09 Sep 2024 Updated efficacy data from a phase II trial in Type 2 diabetes mellitus was presented at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD-2024)
  • 20 May 2024 Efficacy, safety, pharmacokinetics and pharmacodynamics data from a phase I trial in Type 2 diabetes mellitus released by Arecor Limited

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top